Beta Alanine Supplementation
Conditions
Keywords
Chronic effect, Beta Alanine
Brief summary
Randomized, controlled, double-blind, single-center, controlled clinical trial with three parallel arms depending on the product consumed (experimental product dose 1 and dose 2 and placebo product) to measure the efficacy of 28-day consumption of a sustained-release beta alanine on the physiological efficacy of physical performance in recreational cyclists.
Detailed description
Subjects meeting the selection criteria will be randomly assigned to each of the study groups (investigational product dose 1 or dose 2, or placebo, depending on the group to which they have been assigned). The product to be consumed is beta alanine. Participants will consume the product for 28 days. They will have to take 4 intakes every three hours, the first intake being two hours after waking up. The study subjects will have to make 2 visits to the laboratory. Physical performance and physiological changes will be evaluated with a 10-minute time trial. The first test will be performed without product consumption and the second after 28 days of consumption.
Interventions
DIETARY_SUPPLEMENTBeta Alanine high dose
4 intakes of 5 g of beta alanine every 3 hour.
DIETARY_SUPPLEMENTBeta Alanine low dose
4 intakes of 2.5 g of beta alanine every 3 hour.
OTHERControl group
4 intakes of 2.5 g of wheat semolina every 3 hour.
Sponsors
Universidad Católica San Antonio de Murcia
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
MALE
Age
18 Years to 60 Years
Healthy volunteers
Yes
Inclusion criteria
* Male cyclists with more than two years of cycling experience. * Perform tests without fatigue. * Road bike training at least twice a week.
Exclusion criteria
* Participants with chronic illness. * Have a long-term injury that prevents you from training in the previous month. * Inability to understand informed consent. * Have consumed beta alanine in the three years prior to the start of the study. * Consumption of other supplements that may alter performance.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Power | It will be measured on two different occasions. The first day and twenty-eight days later. | Physical performance is measured by direct variables evaluated by the power roller (average power, maximum power, etc.). |
| Distance covered | It will be measured on two different occasions. The first day and twenty-eight days later. | Physical performance is measured by direct variables evaluated by the power roller. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Microcapillary blood | It will be measured on two different occasions. Day one and twenty-eight days later. | This test provides biochemical variables (ABL90FLEX) with 70 ml of capillary blood (Na, K, Glucose, Lactate, etc). It is used to evaluate the effort made by the cyclist. |
| Lactate | It will be measured on two different occasions. Day one and twenty-eight days later. | Lactate levels will be measured using the Lactate Pro |
| Heart Rate | It will be measured on two different occasions. Day one and twenty-eight days later. | The heart rate will be evaluated by means of a heart rate strap. |
| Fatigue | Change of baseline rate of perceived exertion at twenty-eight days | Rate of perceived exertion |
| Fat mass | The test will be measured at baseline and after 28 days of consumption. | It is a control variable. Measured by bioimpedance. |
| Muscle mass | The test will be measured at baseline and after 28 days of consumption. | It is a control variable. Measured by bioimpedance. |
| Liver safety variables | It will be measured twice, once at baseline or at the end of the study after 28 days. | It is a blood test that measures the presence of some enzymes, proteins and bilirubin in the blood, with the aim of determining if there is any alteration in the liver. Enzyme GPT, GOT, Gamma GT, LDH, alkaline phosphatase and bilirubin (UI/L) |
| Body weight | The test will be measured at baseline and after 28 days of consumption. | It is a control variable. Measured by bioimpedance. |
| Paresthesia test | It will be measured on two different occasions. on day 1 (before consumption) and twenty-eight days after (after consumption). | Visual analogue scale (1-10) |
Countries
Spain
Outcome results
None listed